Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 14/20 | 0.56 |
| ▸ | F10 | P00742 | 6/20 | 0.56 |
| ▸ | PLG | P00747 | 5/20 | 0.56 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.56 |
| ▸ | PROC | P04070 | 1/20 | 0.56 |
| ▸ | F11 | P03951 | 1/20 | 0.50 |
| ▸ | TMPRSS11D | O60235 | 4/20 | 0.49 |
| ▸ | TMPRSS6 | Q8IU80 | 8/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8346530 | 0.91 | F2 (0.57) | F2F10PLGTMPRSS11DTMPRSS6 | |
| SCHEMBL8345186 | 0.91 | F2 (0.51) | F2F10PLGKLKB1PROC | |
| SCHEMBL8358012 | 0.88 | F2 (0.52) | F2F10PLGKLKB1PROC | |
| SCHEMBL8345195 | 0.87 | F2 (0.49) | F2F10PLGKLKB1PROC | |
| SCHEMBL8358388 | 0.86 | F2 (0.59) | F2F10PLGKLKB1PROC | |
| SCHEMBL12156653 | 0.83 | F2 (0.61) | F2F10PLGKLKB1PROC | |
| SCHEMBL8220846 | 0.82 | F2 (0.62) | F2F10PLGKLKB1PROC | |
| SCHEMBL8289962 | 0.82 | F2 (0.54) | F2F10PLGKLKB1PROC | |
| SCHEMBL8289816 | 0.82 | F2 (0.54) | F2F10PLGKLKB1PROC | |
| SCHEMBL8291001 | 0.81 | F10 (0.56) | F2F10PLGKLKB1PROC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476306-B2 | Urokinase inhibitors, production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20110065799-A1 | UROKINASE INHIBITORS, PRODUCTION AND USE THEREOF | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-03-17 | — | — | US | disclosed |
| US-7838560-B2 | for the therapy, prophylaxis and diagnosis of a tumor; benzylsulfonyl-D-Ser-Glu-4-amidinobenzylamidexTFA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-7838560-B2 | for the therapy, prophylaxis and diagnosis of a tumor; benzylsulfonyl-D-Ser-Glu-4-amidinobenzylamidexTFA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| WO-2003076391-A2 | UROKINASE INHIBITORS, PRODUCTION AND USE THEREOF | CURACYTE AG (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065799-A1 | UROKINASE INHIBITORS, PRODUCTION AND USE THEREOF | PLAU, PLAUR, SERPINE1 | F2 61/4885F10 94/4885PLG 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.